AIM: To evaluate the effectiveness of montelukast as add-on therapy for asthmatic patients who remain uncontrolled with low, moderate or high doses of inhaled corticosteroid monotherapy. DESIGN: An eight-week, multicentre, open-label, observational study. RESULTS: Of 320 patients enrolled, 288 (90.0%) completed the study. Of patients who had uncontrolled asthma symptoms (Canadian Asthma Consensus Guidelines Update, 2003) but were controlled according to the Asthma Control Questionnaire (ACQ score of less than 1.5), 93.9% maintained asthma control at week 8. Of patients with uncontrolled asthma at baseline for both definitions, 63.5% achieved asthma control by week 8. The mean +/- SD ACQ score decreased from 1.13+/-0.28 to 0.57+/-0.50 (P<0.001) for controlled patients at baseline and from 2.38+/-0.73 to 1.03+/-0.80 (P<0.001) for patients who were uncontrolled at baseline, each representing a clinically significant improvement. CONCLUSION:Montelukast add-on therapy is an effective alternative to inhaled corticosteroid monotherapy.
RCT Entities:
AIM: To evaluate the effectiveness of montelukast as add-on therapy for asthmatic patients who remain uncontrolled with low, moderate or high doses of inhaled corticosteroid monotherapy. DESIGN: An eight-week, multicentre, open-label, observational study. RESULTS: Of 320 patients enrolled, 288 (90.0%) completed the study. Of patients who had uncontrolled asthma symptoms (Canadian Asthma Consensus Guidelines Update, 2003) but were controlled according to the Asthma Control Questionnaire (ACQ score of less than 1.5), 93.9% maintained asthma control at week 8. Of patients with uncontrolled asthma at baseline for both definitions, 63.5% achieved asthma control by week 8. The mean +/- SD ACQ score decreased from 1.13+/-0.28 to 0.57+/-0.50 (P<0.001) for controlled patients at baseline and from 2.38+/-0.73 to 1.03+/-0.80 (P<0.001) for patients who were uncontrolled at baseline, each representing a clinically significant improvement. CONCLUSION:Montelukast add-on therapy is an effective alternative to inhaled corticosteroid monotherapy.
Authors: Lotte van den Nieuwenhof; Tjard Schermer; Petra Eysink; Eric Halet; Chris van Weel; Patrick Bindels; Ben Bottema Journal: Fam Pract Date: 2006-07-31 Impact factor: 2.267
Authors: K Malmstrom; G Rodriguez-Gomez; J Guerra; C Villaran; A Piñeiro; L X Wei; B C Seidenberg; T F Reiss Journal: Ann Intern Med Date: 1999-03-16 Impact factor: 25.391
Authors: E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar Journal: Eur Respir J Date: 2008-01 Impact factor: 16.671
Authors: Young Min Ye; Sang Ha Kim; Gyu Young Hur; Joo Hee Kim; Jung Won Park; Jae Jeong Shim; Ki Suck Jung; Hyun Young Lee; Hae Sim Park Journal: Allergy Asthma Immunol Res Date: 2015-04-07 Impact factor: 5.764